PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
-12.41%
Revenue decline while Biotechnology median is 0.00%. Seth Klarman would investigate if market share loss is temporary.
No Data
No Data available this quarter, please select a different quarter.
-12.41%
Gross profit decline while Biotechnology median is 0.00%. Seth Klarman would investigate competitive position.
No Data
No Data available this quarter, please select a different quarter.
29.66%
R&D growth exceeding 1.5x Biotechnology median of 1.31%. Jim Chanos would check for wasteful spending.
16.61%
G&A change of 16.61% versus flat Biotechnology overhead. Walter Schloss would verify efficiency.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
25.48%
Operating expenses growth exceeding 1.5x Biotechnology median of 3.56%. Jim Chanos would check for waste.
25.48%
Total costs growth exceeding 1.5x Biotechnology median of 3.35%. Jim Chanos would check for waste.
No Data
No Data available this quarter, please select a different quarter.
3.10%
D&A growth exceeding 1.5x Biotechnology median of 0.25%. Jim Chanos would check for overinvestment.
-28.10%
EBITDA decline while Biotechnology median is -1.79%. Seth Klarman would investigate causes.
-46.25%
EBITDA margin decline while Biotechnology median is 0.00%. Seth Klarman would investigate causes.
-27.47%
Operating income decline while Biotechnology median is -3.74%. Seth Klarman would investigate causes.
-45.52%
Operating margin decline while Biotechnology median is 0.00%. Seth Klarman would investigate causes.
-14.81%
Other expenses reduction while Biotechnology median is 0.00%. Seth Klarman would investigate advantages.
-27.92%
Pre-tax income decline while Biotechnology median is -2.91%. Seth Klarman would investigate causes.
-46.04%
Pre-tax margin decline while Biotechnology median is 0.00%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
-27.92%
Net income decline while Biotechnology median is -2.69%. Seth Klarman would investigate causes.
-46.04%
Net margin decline while Biotechnology median is 0.00%. Seth Klarman would investigate causes.
-20.00%
EPS decline while Biotechnology median is 0.00%. Seth Klarman would investigate causes.
-20.00%
Diluted EPS decline while Biotechnology median is 0.00%. Seth Klarman would investigate causes.
6.47%
Share count reduction below 50% of Biotechnology median of 0.41%. Jim Chanos would check for issues.
6.47%
Diluted share reduction below 50% of Biotechnology median of 0.40%. Jim Chanos would check for issues.